Document Detail


World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation.
MedLine Citation:
PMID:  22884380     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.
Authors:
James C Fang; Teresa DeMarco; Michael M Givertz; Barry A Borlaug; Gregory D Lewis; J Eduardo Rame; Mardi Gomberg-Maitland; Srinivas Murali; Robert P Frantz; Dana McGlothlin; Evelyn M Horn; Raymond L Benza
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  31     ISSN:  1557-3117     ISO Abbreviation:  J. Heart Lung Transplant.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-13     Completed Date:  2013-01-14     Revised Date:  2013-03-07    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  913-33     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Affiliation:
Division of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH, USA. james.fang@uhhospitals.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Heart Diseases / complications*
Heart-Assist Devices
Humans
Hypertension, Pulmonary / diagnosis*,  etiology,  physiopathology,  therapy*
Mitral Valve Insufficiency / complications
Mitral Valve Stenosis / complications
Phosphodiesterase Inhibitors / therapeutic use
Receptors, Endothelin / antagonists & inhibitors
Vasodilator Agents / therapeutic use
Grant Support
ID/Acronym/Agency:
K23-HL091106/HL/NHLBI NIH HHS; U01-HL084877/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Receptors, Endothelin; 0/Vasodilator Agents
Comments/Corrections
Erratum In:
J Heart Lung Transplant. 2013 Feb;32(2):275

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Profitability and occupational injuries in U.S. underground coal mines.
Next Document:  Interval versus continuous training in lung transplant candidates: A randomized trial.